Multimodal EPs predict no evidence of disease activity at two years of first line multiple sclerosis treatment (P4.386)

Objective: Determine the prognostic value of evoked potentials (EPs) in patients with Multiple sclerosis Background: No data are available about predictive value of EPs on NEDA evolution Design/Methods: 96 MS patients underwent multimodal EP (VEP-BAEP-SEP-MEP) at first-line treatment initiation. All patients received 2.5±0.8 years clinical and neuro-radiological follow-up; 55 received a 5 years follow-up ± 3 months. Each EPs was assessed with an abnormality score (0 to 3). Maximum multimodal EP score (GEPs) 36 Results: 35/96 patients reached NEDA criteria at follow-up. Mean EP score was 4.09 in NEDA patients and 7.44 in patients with active disease (n=61, 63.5%) (Mann-Whitney; p=0.026). We performed a logistic regression to ascertain the effects of GEPs, MRI lesion load, EDSS and disease duration on the likelihood of having NEDA evolution. The model classified 77.1% of cases (p The small number of NEDA patients at 5 years follow-up limited regression analyses (p=n.s.). GEPs correlated with EDSS at 5 years also when we controlled for baseline values of: EDSS; number of relapses one year before treatment initiation; recovery from previous relapse (complete or incomplete); disease duration; brain MRI lesion load (3 classes: 0–2 lesions, 3–8 lesions, >8 lesions); number of spinal cord lesions; presence of gadolinium enhancing lesions (partial correlation coefficient =0.406; p=0.004). A linear regression was performed to determine the association between these variables at baseline and EDSS at 5 years follow up. The model was significant (R2=0,57, p Conclusions: GEPs add prognostic information to the major clinical and MRI data used for treatment decision making process and predict NEDA evolution at two years Disclosure: Dr. Leocani has received personal compensation for activities with Biogen. Dr. Pisa has nothing to disclose. Dr. Bianco has nothing to disclose. Dr. Guerrieri has nothing to disclose. Dr. Di Maggio has nothing to disclose. Dr. Romeo has nothing to disclose. Dr. Moiola has received personal compensation for activities with Genzyme-Sanofi, Biogen, MerkSerono, and Novartis Pharmaceuticals as an employee. Dr. Martinelli has received personal compensation for activities with Biogen Idec, Merck Serono, Bayer Schering Pharma, Teva Pharmaceutical Industries Ltd., and sanofi-aventi. Prof. Comi has received personal compensation for activities with Novartis, Teva Pharmaceutical Ind. Ltd, Sanofi, Genzyme, Merck Serono, Bayer, Actelion Sano as a speaker, consultant or participating on an advisory board.